Author
Listed:
- Yuqin Song
(Peking University Cancer Hospital & Institute)
- Jun Ma
(Harbin Institute of Hematology & Oncology)
- Huilai Zhang
(Tianjin Medical University Cancer Institute and Hospital)
- Yan Xie
(Peking University Cancer Hospital & Institute)
- Zhigang Peng
(The First Affiliated Hospital of Guangxi Medical University)
- Yuerong Shuang
(Jiangxi Cancer Hospital)
- Fei Li
(The First Affiliated Hospital of Nanchang University)
- Yufu Li
(Henan Cancer Hospital)
- Haiyan Yang
(Zhejiang Cancer Hospital)
- Liqun Zou
(West China Hospital of Sichuan University)
- Xiuhua Sun
(The Second Hospital of Dalian Medical University)
- Weili Zhao
(Shanghai Jiaotong University School of Medicine)
- Wenrong Huang
(The Fifth Medical Center of the General Hospital of the Chinese People’s Liberation Army)
- Yunhong Huang
(The Affiliated Cancer Hospital of Guizhou Medical University)
- Hui Zhou
(Hunan Cancer Hospital)
- Yifan Wang
(Shanghai Junshi Biosciences)
- Weiwei Wang
(Shanghai Junshi Biosciences)
- Jing Xu
(Shanghai Junshi Biosciences)
- Rong Deng
(Shanghai Junshi Biosciences)
- Qin Meng
(Shanghai Junshi Biosciences)
- Jun Zhu
(Peking University Cancer Hospital & Institute)
Abstract
Preclinical studies of tifcemalimab (anti-BTLA antibody) in combination with toripalimab (anti-PD-1 antibody) demonstrated synergistic anti-tumor effects. We present the outcomes of tifcemalimab with or without toripalimab in lymphoma patients. This is a 2-part, phase I study (NCT04477772). In Part A (dose escalation based on 3 + 3 design), patients with relapsed or refractory lymphoma received tifcemalimab monotherapy 1, 3 or 10 mg/kg for dose escalation and 3 mg/kg or 200 mg for dose expansion. For Part B (indication expansion), only classical Hodgkin’s lymphoma (cHL) patients were included to receive tifcemalimab 100 or 200 mg plus toripalimab 240 mg due to poor tumor response in other subtypes. The primary endpoints were safety, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). 25 patients in Part A and 46 in Part B were enrolled. No dose-limiting toxicities were observed, and MTD was not reached. The RP2D for tifcemalimab was 200 mg. Adverse events were predominantly Grade 1/2. Grade 3/4 treatment-related adverse events occurred in 3 patients (12·0%) in Part A and 15 patients (32·6%) in Part B. No fatal adverse events were observed. Tifcemalimab with or without toripalimab demonstrated a favorable safety profile in lymphoma patients.
Suggested Citation
Yuqin Song & Jun Ma & Huilai Zhang & Yan Xie & Zhigang Peng & Yuerong Shuang & Fei Li & Yufu Li & Haiyan Yang & Liqun Zou & Xiuhua Sun & Weili Zhao & Wenrong Huang & Yunhong Huang & Hui Zhou & Yifan W, 2025.
"Tifcemalimab as monotherapy or in combination with toripalimab in patients with relapsed/refractory lymphoma: a Phase I trial,"
Nature Communications, Nature, vol. 16(1), pages 1-9, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59461-3
DOI: 10.1038/s41467-025-59461-3
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59461-3. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.